Immutep halts late-stage trial for lead asset after efficacy analysis
Source: SeekingAlpha
2026-03-13 06:53:07 ET
More on Immutep
- Seeking Alpha’s Quant Rating on Immutep
- Historical earnings data for Immutep
- Financial information for Immutep
Read the full article on Seeking Alpha
For further details see:
Immutep halts late-stage trial for lead asset after efficacy analysis
Merck & Company Inc.
NASDAQ: MRK
MRK Trading
1.11% G/L:
$116.48 Last:
2,106,719 Volume:
$116.92 Open:
MRK Latest News
March 05, 2026 10:20:00 am
Forget ImmunityBio: This Big?Cap Pharma Is the Safer Play on Next?Gen Cancer Therapies
March 03, 2026 09:00:00 am
Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion
MRK Stock Data
$291,612,827,755
2,457,202,311
0.02%
2165
N/A
Pharmaceuticals
Healthcare
US
Rahway
